Add BrightSurf on Google Email

Liverpool begins first human trial of new Zika vaccine

The University of Liverpool is conducting a Phase I trial of a new Zika virus vaccine designed for pregnant women, which has shown promising results in animal studies. The vaccine aims to generate highly protective and long-lasting immunity against the mosquito-borne virus that can cause severe foetal birth defects.

SourceUniversity of Liverpool·TypeRandomized controlled/clinical trial·DateApr 27, 2023

New, comprehensive systematic review and meta-analysis illustrate the need for nuance in public health guidance related to consumption of sugars

A comprehensive review of 169 clinical trials found that the effect of fructose-containing sugars on adiposity varies among food sources and energy control. High doses of certain sources, like SSBs, lead to increased body weight, while others, such as fruit and honey, show moderate beneficial effects when consumed in moderation.

SourceAmerican Society for Nutrition·JournalAmerican Journal of Clinical Nutrition·TypeSystematic review·DateApr 26, 2023

Study finds stool transplants more effective than antibiotics for treating recurring, life-threatening gut infections

A new Cochrane Review found that stool transplantation can increase the number of people recovering from Clostridioides difficile (C. diff) infection by 77%, compared to 40% with standard antibiotic treatment. The study also showed a decrease in side effects with stool transplantation.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateApr 24, 2023

International study recommends replacing skull section after treatment for a brain bleed

A major international trial concludes that surgeons should replace the removed skull section after treating a brain bleed, saving patients from further complications. The study found no significant difference in disability-related and quality-of-life outcomes between the two approaches.

SourceUniversity of Cambridge·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateApr 23, 2023

UHN Researchers publish ground breaking clinical trial in lung transplantation

A study of 70 patients found that donor lungs remained healthy and viable for transplant up to four times longer when stored at 10 degrees Celsius compared to the current standard. This breakthrough could increase donor organs and change practice worldwide, reducing hospital resources and improving patient outcomes.

SourceUniversity Health Network·JournalNEJM Evidence·TypeRandomized controlled/clinical trial·DateApr 20, 2023

A myth no more: Cranberry products can prevent urinary tract infections for women

A global study published in Cochrane Reviews found that consuming cranberry products reduces the risk of repeat symptomatic UTIs in women by more than a quarter. The review also showed benefits for children and people susceptible to UTIs following medical interventions, with minimal side effects reported.

SourceFlinders University·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateApr 19, 2023

Cancer prevention with rapamycin

Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateApr 17, 2023

National Cancer Centre Singapore leads Phase I to IV local and international oncology clinical trials

The National Cancer Centre Singapore has strengthened its position as a leader in shaping local and international clinical trials targeted at improving outcomes for Asian cancers. A pivotal phase III trial co-chaired by a NCCS clinician scientist delivered positive results, increasing recurrence-free survival of patients with hepatocel...

SourceSingHealth·JournalNature Communications·DateApr 17, 2023

Risks of removing ovaries at benign hysterectomy may outweigh the benefits for women at low risk for ovarian cancer

Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeObservational study·DateApr 17, 2023

SWOG S1512 trial sees high response rate to pembrolizumab in patients with unresectable desmoplastic melanoma

A recent clinical trial found that nearly 90% of patients with unresectable desmoplastic melanoma responded to treatment with pembrolizumab. The immunotherapy drug showed impressive results in both treatable and inoperable cases, suggesting a promising treatment option for this rare form of skin cancer.

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateApr 16, 2023

Sex of blood donor has no effect on recipient survival

A large clinical trial of over 8,700 patients found that the sex of a donor has no effect on the survival of recipients of red blood cell transfusions. The study used a pragmatic approach to answer the question definitively and was conducted at a lower cost than typical trials.

SourceThe Ottawa Hospital·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateApr 12, 2023

Refining your search: A team approach to identifying patient cohorts using data from the electronic health record

A team approach to identifying patient cohorts using EHR data improves matching rates for certain e-phenotypes, such as infection and cancer. However, results vary across specialties and phenotypes, highlighting the need for expert collaboration in building accurate search queries.

SourceMedical University of South Carolina·JournalJournal of the American Medical Informatics Association·TypeExperimental study·DateApr 12, 2023

Lifesaving drug for severe bleeding after childbirth could be made accessible for all, study suggests

Researchers from the London School of Hygiene & Tropical Medicine found that intramuscular administration of tranexamic acid (TXA) is safe and quickly reaches therapeutic concentrations in pregnant women. Oral TXA was also well-tolerated but took an hour to reach therapeutic blood concentrations.

SourceLondon School of Hygiene & Tropical Medicine·JournalBritish Journal of Obstetrics and Gynaecology·TypeRandomized controlled/clinical trial·DateApr 5, 2023

Strength training reduces BP when practiced with moderate to vigorous intensity two or three times a week

A systematic review of clinical trials found that strength training with moderate to vigorous intensity, two or three times a week, can significantly lower blood pressure in hypertensive patients. The study analyzed over 21,000 scientific articles and concluded that effective results appeared around the twentieth training session.

Researchers announce findings from landmark clinical trial for pediatric Crohn’s disease

Researchers from the University of North Carolina Health Care announce that patients receiving anti-TNF biologic treatments combined with methotrexate had better outcomes than those treated with adalimumab alone. The study, published in Gastroenterology, provides clear results that can immediately impact patient care.

SourceUniversity of North Carolina Health Care·JournalGASTROENTEROLOGY·TypeRandomized controlled/clinical trial·DateApr 3, 2023

A video-based decision support tool may aid decision-making for Black individuals considering ICD implantation

A randomized clinical trial found that a video-based decision support tool increased patient knowledge, but not assent, to ICD implantation among Black patients. The study also highlighted the complexity of aversion to cardiac procedures in Black communities, emphasizing the need for further research on social determinants of health.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateApr 3, 2023

NRG Oncology combined trial long-term results indicate that pathologic complete response is prognostic of outcomes for soft tissue sarcoma patients

The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.

SourceNRG Oncology·JournalJAMA Oncology·DateMar 31, 2023

University Hospitals research published in New England Journal of Medicine shows minimally invasive procedure saves most patients with severe vascular disease from amputation

The PROMISE II clinical trial showed that LimFlow therapy enabled 76% of patients to avoid amputation and experience wound healing. This minimally invasive procedure bypasses blocked arteries in the leg and rushes blood back into the foot through the veins, providing a unique alternative to major amputation.

SourceUniversity Hospitals Cleveland Medical Center·JournalNew England Journal of Medicine·DateMar 30, 2023

Buprenorphine initiation in the ER found safe and effective for individuals with opioid use disorder who use fentanyl

A multi-site NIH study shows that less than 1% of people with opioid use disorder experience withdrawal when starting buprenorphine in the emergency department. The findings provide strong evidence for safe and effective buprenorphine treatment, even for those using stronger opioids like fentanyl.

SourceNIH/National Institute on Drug Abuse·JournalJAMA Network Open·DateMar 30, 2023

Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease

Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.

Late-breaking results of NRG-GY018 presented at SGO 2023: study demonstrates improved PFS outcomes with the addition of pembrolizumab to chemotherapy for women with advanced or recurrent endometrial cancer

The NRG-GY018 trial found that pembrolizumab significantly improved progression-free survival outcomes in women with stage III-IV or recurrent endometrial cancer, particularly those with mismatch repair deficient tumors. The treatment also demonstrated improved overall survival and quality of life outcomes.

ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer

The ENGOT-EN6-NSGO/GOG-3031/RUBY trial reveals significant improvements in progression-free survival and overall survival for patients with primary advanced or recurrent endometrial cancer when treated with dostarlimab in combination with standard of care carboplatin/paclitaxel. The new treatment regimen offers a substantial increase i...

SourceThe GOG Foundation Inc·TypeRandomized controlled/clinical trial·DateMar 27, 2023

New in The Lancet Neurology: Advances in brain modelling open a path to digital twin approaches for brain medicine

Researchers at the Human Brain Project present novel clinical uses of advanced brain modelling methods, enabling clinicians to simulate epileptic seizures and identify target areas. The approach has broad applicability in neuroscience, medicine, and neurotechnology, with potential improvements in data resolution and patient specificity.

SourceHuman Brain Project·JournalThe Lancet Neurology·DateMar 27, 2023

The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, sponsored by the GOG, investigating the combination of ribociclib and letrozole in patients with recurrent low-grade serous ovarian cancer (LGSOC) (GO

A phase II trial investigating the combination of ribociclib and letrozole showed a response rate of 23%, progression-free survival of 19.1 months, and duration of response of 19.1 months in patients with recurrent low-grade serous ovarian cancer.

SourceThe GOG Foundation Inc·TypeRandomized controlled/clinical trial·DateMar 25, 2023

The addition of gemcitabine with cisplatin and intensity-modulated radiation therapy improves outcomes for women with locally advanced vulvar cancer

Women with locally advanced squamous cell carcinoma of the vulva who received gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy exhibited increased rates of pathologic complete responses. The study found improved survival and response outcomes for this population, while minimizing toxicity.

The utilization of atezolizumab as a primer for chemoradiation results in promising immune system alterations for women with locally advanced cervical cancer

The NRG-GY017 trial found that atezolizumab improved 2-year disease-free survival rates (79% vs. 59%) and pathologically complete or partial responses (69% vs. 40%) for patients with locally advanced cervical cancer. The study also showed a favorable immune response, including positive PD-L1 scoring and T-cell receptor clonal expansion.

Psychological support enhances quality of life for women with endometriosis

A new study from Aarhus University reveals that women with endometriosis can significantly improve their quality of life through psychological therapy, reducing symptoms such as pain and constipation. The trial shows that mindfulness and acceptance-based interventions are equally effective in improving quality of life.

SourceAarhus University·JournalQuality of Life Research·TypeRandomized controlled/clinical trial·DateMar 23, 2023

Potential relief for osteoarthritis moves to clinical trial after animal studies

Researchers have found a potential treatment for osteoarthritis by targeting the GP130 immune receptor, which causes hyper-inflammation in joints. The new compound R805/CX-011 showed promising results in animal studies, reducing joint pain and stiffness, and may lead to Phase 1 and 2A clinical trials.

SourceKeck School of Medicine of USC·JournalScience Translational Medicine·TypeExperimental study·DateMar 22, 2023

Study shows physical activity prevents, not just delays, cancer recurrence in patients previously treated for colon cancer

Researchers found that physical activity can prevent cancer recurrence in stage III colon cancer patients by lowering the recurrence rate within the first year of treatment. This association persisted for approximately three years after surgery, suggesting a long-term survival benefit.

SourcePennington Biomedical Research Center·JournalBritish Journal of Sports Medicine·TypeRandomized controlled/clinical trial·DateMar 21, 2023

Real-world studies confirm effectiveness of bulevirtide to treat chronic hepatitis D

Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.

SourceElsevier·JournalJournal of Hepatology·TypeExperimental study·DateMar 20, 2023